|
|||||
|
|
Development of leading first-generation vaccines against SARS-CoV-2 |
|
| Affiliation: | 1. Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Washington, DC, USA;2. Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA |
| Abstract: | SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need. |
| Keywords: | SARS-CoV-2 Covid-19 Vaccines Clinical trials Animal models |
| 本文献已被 ScienceDirect 等数据库收录！ | |